Cannabinoids in addiction therapy - Focus on methamphetamines

The endocannabinoid system, part of the onboard cell-signaling system in mammals, has a clear role to play in substance-abuse disorders. On the evidence of animal models, this may extend to methamphetamines, where it is posited that the addiction process may be mediated by arachidonic acid cascade. In rats, 3,4 Methylenedioxymethamphetamine-conditioned place preference changes onpre-treatment with the experimental CB1 receptor antagonist 141716A.In rats trained to self-administer methamphetamine, intake has also significantly decreased with antagonist AM 251 pre-treatment, in a dose-dependant manner. Finally, pretreatment with ORG27569, a negative CB1 allosteric modulator, has also resulted in a dose-related attenuation of cue- and drug-induced reinstatement of methamphetamine-seeking behavior. It is not unreasonable to think that cannabidiol (CBD) could function in a future pharmacological therapy in methamphetamine abuse. CBD counteracts amphetamine-induced neuronal sensitization of the mesolimbic dopamine pathway, through a mTOR/p70S6 kinase signaling pathway. 

PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis but without residual cannabinoids like THC or any of the impurities or chemicals associated with plant-derived production processes. Our molecular assembly technique, that synthesizes CBD from aromatic terpenes instead of cannabis, assures you the food and pharmaceutical-grade quality that you need for quality-conscious customers. If you are interested in PureForm CBD™ or want to partner on any other of the 140+ known cannabinoids, please contact Damian Peters at 310-666-4869, or emailinfo@pureformglobal.com. 

The foregoing is a report on trends and developments in the cannabinoid industry. No product described herein is intended to diagnose, treat, cure or prevent any disease or syndrome.